Effect of Tangshenqing on Transcription and Expression of AngⅡ and TGF- in Rats' Renal Tissue

ZHANG Run-yun; ZHENG Yan-fei; LIU Hui; SUN Cui-ying; TAN Ling; LIU Bo; CHEN Yi; MENG Feng-xian

您当前的位置：

首页 >

文章列表页 >

Effect of Tangshenqing on Transcription and Expression of AngⅡ and TGF- in Rats' Renal Tissue

更新时间：2024-01-04

- Effect of Tangshenqing on Transcription and Expression of AngⅡ and TGF- in Rats' Renal Tissue
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 17, Issue 22, Pages: 158-163(2011)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：
  CLC：
- Published：2011
- 稿件说明：
移动端阅览
ZHANG Run-yun, ZHENG Yan-fei, LIU Hui, et al. Effect of Tangshenqing on Transcription and Expression of AngⅡ and TGF- in Rats' Renal Tissue[J]. Chinese journal of experimental traditional medical formulae, 2011, 17(22): 158-163.
DOI：

ZHANG Run-yun, ZHENG Yan-fei, LIU Hui, et al. Effect of Tangshenqing on Transcription and Expression of AngⅡ and TGF- in Rats' Renal Tissue[J]. Chinese journal of experimental traditional medical formulae, 2011, 17(22): 158-163. DOI：

摘要

目的: 观察中药糖肾清1号对糖尿病肾病肾组织局部AngⅡ及TGFβ1 mRNA转录表达及蛋白表达水平的影响。方法: 建立糖尿病肾病大鼠模型

设空白组、模型组、阳性药对照组(卡托普利24 mg·kg-1·d-1)、糖肾清1号甲、乙、丙、丁的高、中、低剂量治疗组(甲组给药糖肾清1号有效成分 A

高剂量组94 mg·kg-1·d-1

中剂量组47 mg·kg-1·d-1

低剂量组23.5 mg·kg-1·d-1。乙组给药糖肾清1号有效成分B

高剂量组94 mg·kg-1·d-1

中剂量组47 mg·kg-1·d-1

低剂量组23.5 mg·kg-1·d-1。丙组用药为1/2A与1/2B配成

高剂量组94 mg·kg-1·d-1

中剂量组47 mg·kg-1·d-1

低剂量组23.5 mg·kg-1·d-1。丁组为糖肾清1号生药制剂

高剂量组用药为195 mg·kg-1·d-1

中剂量为97.5 mg·kg-1·d-1

低剂量组48.75 mg·kg-1·d-1)

每组10只。分别采用RT-PCR

Western blot

ELISA等方法检测大鼠AngⅡ

TGF-β1 mRNA转录及蛋白表达水平

进行组织形态学观测。结果: 糖肾清1号呈量效依赖性下调AngⅡ

TGF-β1 mRNA转录和蛋白表达(P<0.01或0.05)

减少细胞外基质的沉积(P<0.05)。结论: 糖肾清1号可通过调控AngⅡ

TGF-β1 mRNA转录和蛋白表达

抑制肾组织纤维化的发生发展。

Abstract

Objective :To observe the effect of Tangshenqing No. 1 on the transcription and expression of AngⅡ and TGFβ1 in the renal issue. Method : One hundred and forty-six rats were divided into control group(six rats)

model group(10 rats)

active-drug controlled group(10 rats)

and four treatment groups by Tangshengqing No. 1

each designed as low-dose

mid-dose and high-dose groups(10 rats/group). AngⅡ and TGF-β1 were tested by RT-PCR

Western blot

immunohistochemistry and pathomorphology. Result : Rats in treatment groups showed a significant down-regulated expression of mRNA and protein(P<0.01 or P<0.05); ECM sediment was also decreased(P<0.05). Conclusion :Tangshenqing No. 1 can curb the development of renal tissue fibrosis by regulate the mRNA transcription and protein expression of AngⅡ

TGF-β1.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Clinical Observation and Mechanism Study of Xu's Shenqi Yizhu Decoction Combined with Chemotherapy in the Treatment of Cancer-related Fatigue of Stagnated-toxin Spleen Deficiency Type in Postoperative Gastric Cancer Patients

Mechanism of Modified Shaofu Zhuyutang in Antagonising Ectopic Endometrial Tissue Fibrosis Based on Cellular Pyroptosis Mediated by TRL4/NF-κB/NLPR3 Signaling Pathway

Effect of Active Ingredients of Rehmanniae Radix in Intervening Acute Kidney Injury and Fibrosis： A Review

Traditional Chinese Medicine Against Fibrotic Diseases： A Review

Role of Histone Methyltransferase in Fibrosis and Traditional Chinese Medicine Treatment： A Review

Related Author

SHEN Zhixiang

LU Weimin

SHI Chuan

YE Mengwei

LEI Mengyuan

LIU Ziyun

ZHANG Zuoliang

WANG Jiaxing

Related Institution

Affiliated Hospital of Nanjing University of Chinese Medicine

Outpatient Department， Affiliated Hospital of Gansu University of Chinese Medicine

Clinical College of Chinese Medicine， Gansu University of Chinese Medicine

Shandong University of Traditional Chinese Medicine

Xiyuan Hospital， China Academy of Chinese Medical Sciences

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰